121 related articles for article (PubMed ID: 7967440)
21. Host immune response in renal cell cancer: interleukin-4 (IL-4) and IL-10 mRNA are frequently detected in freshly collected tumor-infiltrating lymphocytes.
Maeurer MJ; Martin DM; Castelli C; Elder E; Leder G; Storkus WJ; Lotze MT
Cancer Immunol Immunother; 1995 Aug; 41(2):111-21. PubMed ID: 7656270
[TBL] [Abstract][Full Text] [Related]
22. Human renal carcinoma line transfected with interleukin-2 and/or interferon alpha gene(s): implications for live cancer vaccines.
Belldegrun A; Tso CL; Sakata T; Duckett T; Brunda MJ; Barsky SH; Chai J; Kaboo R; Lavey RS; McBride WH
J Natl Cancer Inst; 1993 Feb; 85(3):207-16. PubMed ID: 8423625
[TBL] [Abstract][Full Text] [Related]
23. Tumor associated antigens in human renal cell carcinoma: MHC restricted recognition by cytotoxic T lymphocytes.
Bernhard H; Jäger E; Maeurer MJ; Meyer zum Büschenfelde KH; Knuth A
Tissue Antigens; 1996 Jul; 48(1):22-31. PubMed ID: 8864171
[TBL] [Abstract][Full Text] [Related]
24. Influence of CD80, interleukin-2, and interleukin-7 expression in human renal cell carcinoma on the expansion, function, and survival of tumor-specific CTLs.
Frankenberger B; Pohla H; Noessner E; Willimsky G; Papier B; Pezzutto A; Kopp J; Oberneder R; Blankenstein T; Schendel DJ
Clin Cancer Res; 2005 Mar; 11(5):1733-42. PubMed ID: 15755994
[TBL] [Abstract][Full Text] [Related]
25. Induction and clonal expansion of tumor-specific cytotoxic T lymphocytes from renal cell carcinoma patients after stimulation with autologous dendritic cells loaded with tumor cells.
Kurokawa T; Oelke M; Mackensen A
Int J Cancer; 2001 Mar; 91(6):749-56. PubMed ID: 11275975
[TBL] [Abstract][Full Text] [Related]
26. Suppression of lymphokine-activated killer cell generation by tumor-infiltrating lymphocytes.
Chakraborty NG; Sporn JR; Pasquale DR; Ergin MT; Mukherji B
Clin Immunol Immunopathol; 1991 Jun; 59(3):407-16. PubMed ID: 2029793
[TBL] [Abstract][Full Text] [Related]
27. Selective cytokine gene expression in renal cell carcinoma tumor cells and tumor-infiltrating lymphocytes.
Wang Q; Redovan C; Tubbs R; Olencki T; Klein E; Kudoh S; Finke J; Bukowski RM
Int J Cancer; 1995 Jun; 61(6):780-5. PubMed ID: 7790111
[TBL] [Abstract][Full Text] [Related]
28. [Study on adoptive immunotherapy on patients with renal cell carcinoma. I. Functional characteristics of peripheral blood mononuclear cells and serum immunosuppressive factors in patients with renal cell carcinoma].
Usui A
Nihon Hinyokika Gakkai Zasshi; 1990 Jul; 81(7):1051-7. PubMed ID: 2214468
[TBL] [Abstract][Full Text] [Related]
29. Renal-cell carcinoma-specific lysis by cytotoxic T-lymphocyte clones isolated from peripheral blood lymphocytes and tumor-infiltrating lymphocytes.
Brouwenstijn N; Gaugler B; Krüse KM; van der Spek CW; Mulder A; Osanto S; van den Eynde BJ; Schrier PI
Int J Cancer; 1996 Oct; 68(2):177-82. PubMed ID: 8900424
[TBL] [Abstract][Full Text] [Related]
30. Phenotype, cytokine production and cytolytic capacity of fresh (uncultured) tumour-infiltrating T lymphocytes in human renal cell carcinoma.
Van den Hove LE; Van Gool SW; Van Poppel H; Baert L; Coorevits L; Van Damme B; Ceuppens JL
Clin Exp Immunol; 1997 Sep; 109(3):501-9. PubMed ID: 9328129
[TBL] [Abstract][Full Text] [Related]
31. Killing of Fas ligand-resistant renal carcioma cells by interleukin-2- and BCG-activated effector cells.
Brandau S; Suttmann H; Flad HD; Jocham D; Böhle A
Cancer Immunol Immunother; 2000 Sep; 49(7):369-76. PubMed ID: 10999463
[TBL] [Abstract][Full Text] [Related]
32. TNF alpha enhancement of NK and LAK cell functions induced by high-dose IL-2 in human peripheral blood mononuclear cells from patients pretreated with alpha IFN + IL-2.
Favrot M; Combaret V; Blay JY; Capdeville R; Zhou DC; Clapisson G; Chouaib S; Franks CR; Philip T
Eur Cytokine Netw; 1990; 1(4):221-7. PubMed ID: 2104243
[TBL] [Abstract][Full Text] [Related]
33. Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and interleukin-2.
Chang AE; Aruga A; Cameron MJ; Sondak VK; Normolle DP; Fox BA; Shu S
J Clin Oncol; 1997 Feb; 15(2):796-807. PubMed ID: 9053507
[TBL] [Abstract][Full Text] [Related]
34. Increase in the ability of human cancer cells to induce cytotoxic T lymphocytes by ultraviolet irradiation.
Umezu Y; Augustus LB; Seito D; Hayakawa K; Ross MI; Eton O; Swanson DA; Itoh K
Cancer Immunol Immunother; 1993 Nov; 37(6):392-9. PubMed ID: 8242664
[TBL] [Abstract][Full Text] [Related]
35. Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: a pilot study.
Goedegebuure PS; Douville LM; Li H; Richmond GC; Schoof DD; Scavone M; Eberlein TJ
J Clin Oncol; 1995 Aug; 13(8):1939-49. PubMed ID: 7636534
[TBL] [Abstract][Full Text] [Related]
36. Helper T cells infiltrating human renal cell carcinomas have the phenotype of activated memory-like T lymphocytes.
Alexander RB; Fitzgerald EB; Mixon A; Carter CS; Jakobsen M; Cohen PA; Rosenberg SA
J Immunother Emphasis Tumor Immunol; 1995 Jan; 17(1):39-46. PubMed ID: 7728304
[TBL] [Abstract][Full Text] [Related]
37. Immunosensitization of resistant human tumor cells to cytotoxicity by tumor infiltrating lymphocytes.
Frost P; Caliliw R; Belldegrun A; Bonavida B
Int J Oncol; 2003 Feb; 22(2):431-7. PubMed ID: 12527945
[TBL] [Abstract][Full Text] [Related]
38. Effect of B7.1-transfected human colon cancer cells on the induction of autologous tumour-specific cytotoxic T cells.
Miyazono Y; Kamogawa Y; Ryo K; Furukawa T; Mitsuhashi M; Yamauchi K; Kameoka T; Hayashi N
J Gastroenterol Hepatol; 1999 Oct; 14(10):997-1003. PubMed ID: 10530496
[TBL] [Abstract][Full Text] [Related]
39. Combination of lymphokine-activated killer cells and interleukin-2 in treating metastatic renal cell carcinoma.
Fujioka T; Nomura K; Hasegawa M; Ishikura K; Kubo T
Br J Urol; 1994 Jan; 73(1):23-31. PubMed ID: 8298895
[TBL] [Abstract][Full Text] [Related]
40. Human renal-cell carcinoma cells are able to activate natural killer cells.
Hayakawa K; Morita T; Augustus LB; von Eschenbach AC; Itoh K
Int J Cancer; 1992 May; 51(2):290-5. PubMed ID: 1533204
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
